Hoerauf Achim, Specht Sabine, Büttner Marcelle, Pfarr Kenneth, Mand Sabine, Fimmers Rolf, Marfo-Debrekyei Yeboah, Konadu Peter, Debrah Alexander Yaw, Bandi Claudio, Brattig Norbert, Albers Anna, Larbi John, Batsa Linda, Taylor Mark J, Adjei Ohene, Büttner Dietrich W
Institute for Medical Microbiology, Immunology and Parasitology, University Clinic, Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany.
Med Microbiol Immunol. 2008 Sep;197(3):295-311. doi: 10.1007/s00430-007-0062-1. Epub 2007 Nov 13.
In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4-6 weeks, followed by ivermectin (IVM) after 6 months. After 6-27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
在加纳进行的一项随机、安慰剂对照试验中，67名盘尾丝虫病患者接受了为期4 - 6周、每日200毫克的强力霉素治疗，6个月后再接受伊维菌素（IVM）治疗。6 - 27个月后，通过盘尾丝虫瘤组织学、聚合酶链反应（PCR）和微丝蚴测定来评估疗效。强力霉素的给药导致内共生菌减少和雌虫绝育。为期6周的治疗具有杀成虫作用，尽管在服用强力霉素后出现了新的携带沃尔巴克氏体的虫体，但仍有超过60%的雌虫死亡。强力霉素可开发为盘尾丝虫病的二线药物，用于无传播的地区、对伊维菌素有抗性的疫源地以及有罗阿丝虫共感染的地区。
